Lynn Seely - 10 Nov 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
President and CEO, Director
Signature
/s/ Mark Meltz, Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
10 Nov 2025
Net transactions value
-$6,637
Form type
4
Filing time
12 Nov 2025, 20:36:42 UTC
Previous filing
29 Oct 2025
Next filing
11 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Seely Lynn President and CEO, Director C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO /s/ Mark Meltz, Attorney-in-Fact 12 Nov 2025 0001327111

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Sale $6,637 -412 -0.61% $16.11 67,159 10 Nov 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.